Promising new combo targets hard-to-treat breast cancer brain tumors
NCT ID NCT07623577
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two drugs, sacituzumab tirumotecan and bevacizumab, can shrink or control brain tumors in people with triple-negative breast cancer that has spread to the brain. About 24 adults whose cancer cannot be removed by surgery or radiation will receive the treatment. The goal is to see how well the drugs work against brain metastases and how safe they are.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict frailty in serious illness? a large study investigates
- Engineered immune cells take aim at brain tumors
- Could targeted drugs spare brain cancer patients from radiation after surgery?
- Study reveals why immunotherapy works differently in liver, lung, and brain tumors
- New drug combo aims to stop aggressive breast cancer from returning
- Could a common pain pill protect the brain during surgery?